Prostate Cancer Treatment

Global Prostate Cancer Treatment Market to Reach US$31.2 Billion by 2030

The global market for Prostate Cancer Treatment estimated at US$21.4 Billion in the year 2024, is expected to reach US$31.2 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Prostate Surgery, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 10.5% CAGR

The Prostate Cancer Treatment market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Prostate Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Prostate Cancer Treatment Experiencing a Shift Toward Personalized and Targeted Therapies?
The prostate cancer treatment market is undergoing a major transformation with the rise of personalized medicine and precision oncology. Prostate cancer, one of the most commonly diagnosed malignancies among men worldwide, has seen expanded treatment options beyond traditional surgery and radiation. New frontiers in immunotherapy, androgen receptor pathway inhibitors, radioligand therapy, and next-generation anti-androgens are now redefining therapeutic paradigms. These developments are being driven by increasing understanding of genetic mutations, hormone responsiveness, and tumor microenvironments that impact disease progression.

Targeted therapies such as PARP inhibitors (e.g., olaparib and rucaparib) are gaining traction among patients with BRCA1/2 or other homologous recombination repair (HRR) gene mutations. These drugs selectively inhibit DNA repair in cancer cells, offering significant clinical benefits in metastatic castration-resistant prostate cancer (mCRPC). Additionally, precision diagnostics like next-generation sequencing (NGS) and liquid biopsy are being used to profile tumor genomics, enabling oncologists to tailor treatment based on molecular signatures. This shift toward genomic-informed decision-making is central to improving survival rates and reducing overtreatment in low-risk patients.

Which Treatment Modalities and Patient Segments Are Reshaping the Market Landscape?
Historically, prostate cancer management relied on surgery (radical prostatectomy), radiation therapy (external beam or brachytherapy), and androgen deprivation therapy (ADT). While these continue to be foundational interventions, the rise in advanced-stage diagnoses and the emergence of hormone-resistant tumors have intensified demand for more sophisticated systemic therapies. In high-risk and metastatic settings, the combination of ADT with next-generation androgen receptor inhibitors such as enzalutamide, apalutamide, and darolutamide has become the new standard of care.

Older patients with comorbidities or low-grade disease increasingly benefit from active surveillance programs, reducing unnecessary exposure to invasive therapies. Conversely, patients with mCRPC are now candidates for radioligand therapies like Lutetium-177-PSMA-617, which deliver targeted radiation to prostate-specific membrane antigen (PSMA)-positive cells. Immunotherapeutics such as sipuleucel-T (Provenge) represent the first wave of cancer vaccines, although adoption remains limited due to logistical complexity and modest efficacy. The patient population is becoming more segmented based on risk stratification, tumor biology, and prior treatment exposure-guiding clinicians toward multi-modal, stage-specific interventions.

How Are Technology, Drug Development, and Regulatory Dynamics Influencing Treatment Access and Innovation?
Innovation in prostate cancer treatment is accelerating due to a robust drug development pipeline and a supportive regulatory environment. Agencies like the U.S. FDA and European Medicines Agency (EMA) have granted priority review and breakthrough designations for several novel therapies, especially those targeting genetic biomarkers. Companies are also leveraging real-world evidence (RWE) and adaptive trial designs to fast-track approvals and post-marketing surveillance. Companion diagnostics are increasingly co-developed with therapies to ensure optimal patient selection, minimizing toxicity and cost inefficiencies.

Advances in robotic-assisted surgery (e.g., Da Vinci systems), intensity-modulated radiation therapy (IMRT), and image-guided brachytherapy are improving treatment precision while minimizing adverse effects. AI-enabled platforms are now being deployed for treatment planning, pathology image interpretation, and progression prediction. Additionally, the integration of telemedicine for follow-ups and PSA monitoring is enhancing continuity of care, especially in rural or underserved regions. Cost remains a barrier in low- and middle-income countries, though international cancer consortia and global access programs are attempting to bridge the therapeutic equity gap.

What Factors Are Driving the Growth of the Global Prostate Cancer Treatment Market?
The growth in the global prostate cancer treatment market is driven by the aging male population, rising incidence of prostate cancer diagnoses, expanding biomarker-driven therapies, and increased payer support for advanced interventions. Improved public awareness and expanded screening programs, particularly in developed regions, are leading to earlier diagnosis and better patient outcomes. Simultaneously, the rising global prevalence of late-stage or aggressive prostate cancer is necessitating the adoption of novel drug classes and precision radiation methods.

Biopharmaceutical innovation is another key growth driver. Several next-generation agents targeting AR-V7 splice variants, PI3K/AKT/mTOR pathways, and DNA damage repair mechanisms are in late-phase clinical development. Partnerships between pharmaceutical companies and diagnostics firms are accelerating market entry of targeted therapies with robust reimbursement frameworks. Emerging markets such as China, Brazil, and India are also witnessing faster regulatory approvals and market access, backed by national cancer control policies and expanded oncology infrastructure.

Key players in the market include Johnson & Johnson (Janssen), Pfizer Inc., Astellas Pharma, Bayer AG, Novartis AG, AstraZeneca, and Telix Pharmaceuticals. These firms are investing in clinical trials, molecular diagnostic tools, and strategic acquisitions to strengthen their prostate oncology portfolios. As treatment approaches shift toward chronic disease management and individualized care, the global market is set to expand across surgical, pharmaceutical, and radiotherapeutic domains.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy Type (Prostate Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy); End-Use (Hospitals End-Use, Clinics End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Dendreon Pharmaceuticals LLC
• Eli Lilly and Company
• Exelixis Inc.
• F. Hoffmann-La Roche AG
• Ferring Pharmaceuticals Inc.
• Fusion Pharmaceuticals Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Myovant Sciences GmbH
• Novartis AG
• Pfizer Inc.
• Point Biopharma
• Sanofi S.A.
• Santen Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals (Bausch)

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more